Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006

Emerging Infectious Diseases

Volumn 15, Issue 9, 2009, Pages 1395-1401

  Bitar, Dounia ^a   Van Cauteren, Dieter ^a   Lanternier, Fanny ^b   Dannaoui, Eric ^d   Che, Didier ^a   Dromer, Francoise ^c   Desenclos, Jean Claude ^a   Lortholary, Olivier ^b,c  

^a INSTITUT DE VEILLE SANITAIRE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT PASTEUR   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; FRANCE; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; MEDICAL RECORD; MIOSIS; MUCORMYCOSIS; RISK FACTOR; ZYGOMYCETES;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; FRANCE; HEMATOLOGIC NEOPLASMS; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MUCORMYCOSIS; RISK FACTORS; YOUNG ADULT; ZYGOMYCOSIS;

EID: 70249091845     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1509.090334     Document Type: Article

References (40)

1. Dromer F, Mc Ginnis MR. Zygomycosis. In: Anaissie EJ, Mc Ginnis MR, Pfaller MA, editors. Clinical mycology. New York: Churchill Livingstone; 2002. p. 297-308.
2. Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis. 2004;17:517-525 DOI: 10.1097/00001432-200412000-00003
3. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000;13:236-301. DOI: 10.1128/CMR.13.2.236-301.2000
4. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18:556-569 DOI: 10.1128/CMR.18.3.556-569.2005 (Pubitemid 40995116)
5. Liang KP, Tleyjeh IM, Wilson WR, Roberts GD, Temesgen Z. Rhino- orbitocerebral mucormycosis caused by Apophysomyces elegans. J Clin Microbiol. 2006;44:892-898 DOI: 10.1128/JCM.44.3.892-898.2006
6. Bouza E, Munoz P, Guinea J. Mucormycosis: an emerging disease? Clin Microbiol Infect. 2006;12(Suppl. 7):7-23. DOI: 10.1111/j.1469-0691.2006.01604.x
7. Chayakulkeeree M, Ghannoum MA, Perfect JR. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis. 2006;25:215-229 DOI: 10.1007/s10096-006-0107-1
8. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634-653 DOI: 10.1086/432579
9. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47:503-509 DOI: 10.1086/590004
10. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med. 2004;350:950-952 DOI: 10.1056/NEJM200402263500923 (Pubitemid 38252550)
11. Dannaoui E, Meis JF, Loebenberg D, Verweij PE. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother. 2003;47:3647-3650 DOI: 10.1128/AAC.47.11.3647-3650.2003 (Pubitemid 37345740)
12. Greenberg RN, Mullane K, van Burik JA, Raad I, Abzug MJ, Anstead G, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006;50:126-133 DOI: 10.1128/AAC.50.1.126-133.2006
13. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis. 2006;42:e61-5. DOI: 10.1086/500212
14. Soummer A, Mathonnet A, Scatton O, Massault PP, Paugam A, Lemiale V, et al. Failure of deferasirox, an iron chelator agent, combined with antifungals in a case of severe zygomycosis. Antimicrob Agents Chemother. 2008;52:1585-1586 DOI: 10.1128/AAC.01611-07
15. Spellberg B, Andes D, Perez M, Anglim A, Bonilla H, Mathisen GE, et al. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother. 2009;53:3122-3125
16. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect. 2004;10(Suppl 1):31-47. DOI: 10.1111/j.1470-9465.2004.00843.x (Pubitemid 38379950)
17. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, et al. Zygomycosis in a tertiary-care cancer center in the era of aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191:1350-1360 DOI: 10.1086/428780 (Pubitemid 40503665)
18. Singh N, Aguadao JM, Bonatti H, Forrest G, Gupta KL, Safdar N, et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis. In press.
19. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, Bartelt LA, Kilborn SB, Hoth PL, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis. 2004;39:584-587 DOI: 10.1086/422723 (Pubitemid 39120940)
20. Vigouroux S, Morin O, Moreau P, Mechinaud F, Morineau N, Mahe B, et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis. 2005;40:e35-7. DOI: 10.1086/427752
21. Buisson G. PMSI- Redressements du programme de médicalisation des systèmes d'informations, N° 80, March 2005. Séries Statistiques -DREES 2007 [cited 2008 May 21]. Available from http://www.sante.gouv.fr/drees/seriestat/seriestat80.htm
22. Gallay A, Vaillant V, Bouvet P, Grimont P, Desenclos JC. How many foodborne outbreaks of Salmonella infection occurred in France in 1995? Application of the capture-recapture method to three surveillance systems. Am J Epidemiol. 2000;152:171-177 DOI: 10.1093/aje/152.2.171
23. Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. Clin Infect Dis. 1998;27:1138-1147 DOI: 10.1086/514975
24. Torres-Narbona M, Guinea J, Martinez-Alarcon J, Munoz P, Gadea I, Bouza E. Impact of zygomycosis on microbiology workload: a survey study in Spain. J Clin Microbiol. 2007;45:2051-2053 DOI: 10.1128/JCM.02473-06 (Pubitemid 46933960)
25. Torres-Narbona M, Guinea J, Martinez-Alarcon J, Munoz P, Pelaez T, Bouza E. Workload and clinical significance of the isolation of zygomycetes in a tertiary general hospital. Med Mycol. 2008;46:225-230 DOI: 10.1080/ 13693780701796973
26. Trevejo RT. Acute encephalitis hospitalizations, California, 1990- 1999: unrecognized arboviral encephalitis? Emerg Infect Dis. 2004;10:1442-1449
27. Chang DC, Burwell LA, Lyon GM, Pappas PG, Chiller TM, Wannemuehler KA, et al. Comparison of the use of administrative data and an active system for surveillance of invasive aspergillosis. Infect Control Hosp Epidemiol. 2008;29:25-30. DOI: 10.1086/524324
28. Carré N, Uhry Z, Velten M, Tretarre B, Schvartz C, Molinie F, et al. Predictive value and sensibility of hospital discharge system (PMSI) compared to cancer registries for thyroid cancer (1999-2000) [in French]. Rev Epidemiol Sante Publique. 2006;54:367-376 DOI: 10.1016/S0398-7620(06)76731-1
29. Geoffroy-Perez B, Imbernon E, Gilg S, I, Goldberg M. Comparison of the French DRG based information system (PMSI) with the National Mesothelioma Surveillance Program database.[In French]. Rev Epidemiol Sante Publique. 2006;54:475-483 DOI: 10.1016/S0398-7620(06)76747-5
30. Hafdi-Nejjari Z, Couris CM, Schott AM, Perrot L, Bourgoin F, Borson- Chazot F, et al. Role of hospital claims databases from care units for estimating thyroid cancer incidence in the Rhone-Alpes region of France [in French]. Rev Epidemiol Sante Publique. 2006;54:391-398 DOI: 10.1016/S0398- 7620(06)76737-2 (Pubitemid 44832111)
31. Tricco AC, Pham B, Rawson NS. Manitoba and Saskatchewan administrative health care utilization databases are used differently to answer epidemiologic research questions. J Clin Epidemiol. 2008;61:192-197 DOI: 10.1016/j.jclinepi. 2007.03.009
32. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909-917 DOI: 10.1086/339202 (Pubitemid 34229758)
33. Blin N, Morineau N, Gaillard F, Morin O, Milpied N, Harousseau JL, et al. Disseminated mucormycosis associated with invasive pulmonary aspergillosis in a patient treated for post-transplant high-grade non-Hodgkin's lymphoma. Leuk Lymphoma. 2004;45:2161-2163 DOI: 10.1080/10428190410001700803 (Pubitemid 39232870)
34. Girmenia C, Moleti ML, Micozzi A, Iori AP, Barberi W, Foa R, et al. Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation. J Clin Microbiol. 2005;43:5395-5396 DOI: 10.1128/JCM.43.10.5395-5396.2005
35. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis. 2004;39:743-746 DOI: 10.1086/423274 (Pubitemid 39180450)
36. Agence de la Biomedecine. Rapport d'activité de l'Agence de la Biomedecine 2007, 234 p. [cited 2009 May 20]. Available from http://www.agence-biomedecine.fr/uploads/document/rapp-synth2007.pdf
37. Kusnik-Joinville O, Weill A, Salanave B, Ricordeau P, Allemand H. Prevalence and treatment of diabetes in France: trends between 2000 and 2005. Diabetes Metab. 2008;34:266-272 DOI: 10.1016/j.diabet.2008.01.005
38. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91:1068-1075 (Pubitemid 44208634)
39. Chakrabarti A, Das A, Mandal J, Shivaprakash MR, George VK, Tarai B, et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol. 2006;44:335-342 DOI: 10.1080/13693780500464930 (Pubitemid 43922068)
40. Perlroth J, Choi B, Spellberg B. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol. 2007;45:321-346 DOI: 10.1080/13693780701218689 (Pubitemid 46839802)